Navigation Links
Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting

nically significant."

Study discontinuations due to adverse events occurred in 11 (4.8%) of the 229 Fampridine-SR-treated patients, and none of the 72 patient placebo group. Three of these events were considered serious: influenza, sepsis and anxiety. The anxiety was considered probably related to treatment. A focal seizure, observed during the sepsis, was considered possibly related to treatment. An additional 13 patients in the Fampridine-SR-treated group experienced various serious adverse events but none of these led to discontinuation from treatment and none was considered related to treatment. Most non-serious adverse events were rated as mild to moderate in intensity and observed at similar rates in Fampridine-SR and placebo groups. Some events were seen more frequently in the Fampridine-SR group (insomnia, fatigue, back pain, balance disorder) while upper respiratory infection was more common in the placebo group. Overall, the safety data were consistent with previous experience.

Study Design

The double-blind, placebo-controlled trial was designed to evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS. The trial, which enrolled 301 individuals at 33 MS centers in the United States and Canada, recruited patients between 18 and 70 years old with a definite diagnosis of MS and some degree of walking disability. The study was open to people with all types of MS, including primary-progressive, secondary-progressive, relapsing-remitting and progressive-relapsing. Participants were permitted to remain on a stable regimen of their current medications, including immunomodulators. Secondary endpoints for the trial included the Lower Extremity Manual Muscle Test, the Ashworth Score for spasticity, and Subject and Clinician Global Impressions. Subjects were randomized to 14 weeks of treatment with Fampridine-SR (n=229) or placebo (n=72), a 3:1 ratio of drug to placebo. The safety measures in this trial in
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
(Date:8/3/2015)... (PK:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2016 ... The Company posted quarterly net revenue of $2.454 million ... $(0.02) per share. These results compare to net revenue ... thousand, or $(0.02) per share, in the year-ago quarter. ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... 15 Watermark Medical , Inc., a privately-held, ... market, has expanded the market reach of its Web-enabled ... three leading sleep solution providers in the U.S. and ... national provider of comprehensive sleep apnea services; Sleep ...
... Vista Partners announced today that it has updated ... Principal Analyst at Vista Partners stated, "Raptor is potentially ... a balanced pipeline of clinical and preclinical programs.  The ... programs and one Phase 3 trial with some indications ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... According to an opinion ... calories out of person’s diet leads to one pound of weight loss may not be ... caloric reduction that translates to one pound of fat varies – based both on the ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading ... HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded by ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... bodybuilding and fitness site and the largest online retailer of nutritional supplements, ... BPI Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... TAMPA, Florida (PRWEB) , ... August 03, 2015 ... ... Association for Physician Leadership ® and Navigant Center for Healthcare Research and Policy ... nationwide. , Fifty-five percent of respondents said they agreed or strongly agreed that ...
(Date:8/3/2015)... ... , ... A July 9 article from USA Today has revealed ... the American Dental Association. According to a study by the American Dental Association, from ... a single year to 2.2 million a year. Dentists and ADA officials all point ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... , This release is available in ... Patients suffering from two serious autoimmune disorders which ... cardiovascular disease, says a group of Montreal researchers. Dr. ... Institute of the McGill University Health Centre (RI-MUHC) have ...
... Additional Speakers and New Sessions Added to ... , , MINNEAPOLIS, Sept. 1 ... has added several speakers and new sessions to the most comprehensive ... Compliance and Ethics Institute, being held September 13 - 16, 2009, ...
... , , , ... Audiopoint, a leading provider of innovative voice data solutions, ... of automated patient management services. NotifierRx will help hospitals ... by automating outpatient follow-up with interactive voice-controlled services. , ...
... , , , OAKLAND, ... of the Thrive advertising campaign, with television, radio, print and online ... health of its members and the communities it serves. , ... -- illustrate Kaiser Permanente,s leadership in leveraging health information technology. As ...
... , , , , ... NTRI ), a leading provider of weight management programs ... to offer consumers striving for a late-summer shape up, some easy, top-of-mind ... long. , , According to Sansone, ...
... Industry Veteran to Lead PI Pharmaceutical Business Unit ... Physicians Interactive LLC (PI), a leader in digital sales and marketing ... Pingle has been named President of PI. Pingle will report to ... lead the company,s pharmaceutical business unit. , , ...
Cached Medicine News:Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2Health News:Cynthia Cooper, Time Magazine's Person of the Year and former WorldCom Auditor to Address the 8th Annual Compliance and Ethics Institute, September 13-16, 2009, Planet Hollywood, Las Vegas, NV 2Health News:Cynthia Cooper, Time Magazine's Person of the Year and former WorldCom Auditor to Address the 8th Annual Compliance and Ethics Institute, September 13-16, 2009, Planet Hollywood, Las Vegas, NV 3Health News:Cynthia Cooper, Time Magazine's Person of the Year and former WorldCom Auditor to Address the 8th Annual Compliance and Ethics Institute, September 13-16, 2009, Planet Hollywood, Las Vegas, NV 4Health News:Cynthia Cooper, Time Magazine's Person of the Year and former WorldCom Auditor to Address the 8th Annual Compliance and Ethics Institute, September 13-16, 2009, Planet Hollywood, Las Vegas, NV 5Health News:Audiopoint Adds Voice to Healthcare Reform Debate 2Health News:Audiopoint Adds Voice to Healthcare Reform Debate 3Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 2Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 3Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 2Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 3Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 4Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 5Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 6Health News:Physicians Interactive Names Sanjay Pingle President 2Health News:Physicians Interactive Names Sanjay Pingle President 3
... Markers have a unique squeezable barrel ... writing over wet prep solutions. Micro ... with optional rulers and sterile labels ... sterile, packaged individually in peel pouches. ...
Broad tip, gentian violet, sterile, disposable...
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
Medicine Products: